System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Marek Trneny is an expert in Hematology at General University Hospital in Prague (Czechia). As of October 2026, ScienceLeadR ranks Marek Trneny in the top 1% of experts worldwide for Lymphoma and Lymphoproliferative Disorders. Marek Trneny has authored 600 publications, the most recent in 2026, and is an investigator in 57 clinical trials, 11 of them ongoing. SLR score: 2,655 (community average: 125). How the SLR is computed.

LeadR Profile

Marek Trneny General University Hospital in Prague Czechia
2 655 ScienceLeadR Reputation 2655

Unlock

Register Login
Network Map

Hematology

Subspecialties: Oncology - Immunology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1994 - 2026
Source: PubMed

Charles University

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 600

Citations

Citations: 23 732 1st author: 26 Last author: 130 Unique author: 2

Main journals

Blood 194
Hematol Oncol 52
J Clin Oncol 50
CL LYMPH MYELOM LEUK 23
Hemasphere 20

Best Journals

J Clin Oncol 30
Lancet Oncol 10
Lancet 5

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Newly diagnosed and relapsed follicular lymphoma: EHA Clinical Practice Guidelines for diagnosis, treatment, and follow-up.
PMID 42903357 — cells, lymphoma, follicular, tomography, lymphoma, neoplasms, tumor burden, diagnosis, therapeutics, receptors, antigen, t-cell		Hemasphere20260
The Baseline Molecular Profile of Late Relapse: Identifying Drivers of Delayed Recurrence in DLBCL.
PMID 42861738 — genomics, gene expression profiling, medical oncology, b-lymphocytes		Hematol Oncol20260
LymphGen-Sig: Integrating Genetic and Transcriptional States to Predict Therapeutic Response in Diffuse Large B-Cell Lymphoma.
PMID 42715516 — cells, genes, lymphoma, b-cell, lymphoma, lymphoma, large b-cell, diffuse, classification, therapeutics, mutation, b-lymphocytes, gene expression		J Clin Oncol Top journal20260
Low lymphoma macrophage infiltration predicts poor outcomes for R-CHOP- but not Pola-R-CHP-treated patients with DLBCL.
PMID 42699559 — lymphoma, macrophages, lymphoma, large b-cell, diffuse, therapeutics		Blood Neoplasia20260
Transforming lymphoma outcomes through international real-world data collaborations: the Global Lymphoma Registry Alliance roadmap.
PMID 42610429 — registries, lymphoma, cooperative behavior, therapeutics		Haematologica20260

Clinical Studies 57

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 2

By phase:

Phase 3 32
Phase 2 13
N/A 6
Phase 1/Phase 2 5
Phase 1 1

By status:

Completed 33
Active not recruiting 12
Recruiting 5
Terminated 3
Not yet recruiting 2
Unknown 2

By type:

Interventional 52
Observational 5

By Monocentric/Multicentric:

monocentric 6
multicentric2to4 0
multicentric5to9 6
multicentricup10 45

Main Topics

Ongoing Clinical Trials

11 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Phase 3 Study Comparing Pirtobrutinib to Ibrutinib in CLL SLL
2023-507699-38-00 — lymphoma, leukemia, lymphocytic, chronic, b-cell, leukemia, leukemia, lymphoid		Phase 3Active not recruiting2022
A Phase 2 Open Label Safety and Efficacy Study of PF 06835375
2023-509338-21-00 — safety, multiple chronic conditions, thrombocytopenia, purpura, thrombocytopenic, idiopathic		Phase 2Recruiting2022
An unblinded multi center study evaluating long term treatment with Zanubrutinib (BGB 3111) regimens in patients with blood cancer in the lymph node
2024-511267-28-00 — cells, blood, lymph nodes, neoplasms, multiple chronic conditions, lymph, therapeutics, b-lymphocytes		Phase 3Active not recruiting2021
CAR T cell treatment for untreated high risk MANtle Cell Lymphoma
2022-502405-15-01 — cells, lymphoma, maintenance, rituximab, lymphoma, mantle-cell, therapeutics, t-lymphocytes, car-t cell		Phase 2Recruiting2024
A Phase 3 study of Tafasitamab plus Lenalidomide in addition to Rituximab versus Lenalidomide plus Rituximab in patients With Relapsed Refractory (R R) Follicular Lymphoma Grade 1 to 3a or R R Marginal Zone Lymphoma
2023-504684-16-00 — lymphoma, follicular, safety, lymphoma, rituximab, lenalidomide, therapeutics		Phase 3Active not recruiting2021

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS